Former GOP Sen. Ben Sasse On ‘Nasty Drug’ to Treat Stage 4 Cancer

“There are not enough treatment options, and our patients don’t have the luxury of waiting years for any regulatory agency to review data,” he explained in an interview with the school’s Department of Medicine.

“The idea that the FDA has a pathway for accelerated review is important and exciting, but it’s a new program, so I think there’s still a lot we’ll have to learn from it,” Lieu noted further.